Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Dr. Christopher B. Wood, Chairman and Chief Executive Officer of the...
Bioenvision, Inc. (NasdaqGM:BIVN) a developer of oncology drugs today announced Joseph P. Cooper has joined its board of...
Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Dr. Christopher B. Wood, Chairman and Chief Executive Officer, is scheduled to present at...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced the latest results from the ongoing European study (BIOV-111) of Evoltra(R) (clofarabine) in...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced it is expanding into Japan and Southeast Asia for the clinical and commercial development of...
Bioenvision, Inc. (NasdaqGM: BIVN) today announced the Company will be formally launching Evoltra(R) throughout Europe at the 38th Congress of the...
Bioenvision (NasdaqGM:BIVN) today announced financial results for its fourth quarter and fiscal year ended June 30, 2006. Highlights of the year...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced results of a randomized Phase II trial of Suvus(TM) in patients with chronic hepatitis C virus...
Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal 2006 year-end financial results at 7 a.m. Eastern Daylight Time on September 11, 2006. ?...
Bioenvision, Inc. (NASDAQ:BIVN) Bioenvision today announced its abstract on Suvus(TM) has been accepted for the British Association for the Study...
Bioenvision (Nasdaq:BIVN) today announced new data from its BIOV-121 non-randomized phase II clinical study which based upon historical controls...
Bioenvision, Inc. (NASDAQ: BIVN) today announced that following selection by the European Hematology Association (EHA), data on it's Evoltra(TM...
Bioenvision (Nasdaq: BIVN) today announced that in the companies pivotal, non-randomized Phase II study (BIOV-121), presented at the 42nd Annual...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.